Clinical Trials Logo

Communicable Diseases clinical trials

View clinical trials related to Communicable Diseases.

Filter by:
  • Withdrawn  
  • Page 1 ·  Next »

NCT ID: NCT06273098 Withdrawn - Clinical trials for Urinary Tract Infections

School-Based Bladder Health Intervention

Start date: January 1, 2028
Phase: N/A
Study type: Interventional

The aim of this study is to promote healthy bladder behaviors among school children. We hypothesize that a combination of bladder health education and awareness events, additional resources such as a water station to support healthy bladder behaviors, and tailored changes to classroom bathroom policies can promote healthy bladder behaviors among school children.

NCT ID: NCT05700630 Withdrawn - HIV-1-infection Clinical Trials

Ph1 Study of FT538 Alone and With Vorinostat for Persistent Low-Level HIV Viremia

Start date: July 15, 2024
Phase: Phase 1
Study type: Interventional

This is a single center Phase I clinical trial of FT538 administered intravenously (IV) once every 14 days for 4 consecutive doses for the reduction of the HIV reservoir in lymphoid tissue of HIV-infected individuals receiving standard of care (SOC) antiretroviral therapy (ART). As this is an early 1st in human study and the 1st for HIV-infected individual, the safety of FT538 is confirmed prior to the addition of oral vorinostat to explore the concept of "Kick and Kill".

NCT ID: NCT05639504 Withdrawn - Sepsis Clinical Trials

Sepsis Prognosis and Diagnosis in the Emergency Department (SPEED)

Start date: December 2022
Phase:
Study type: Observational

This study aims to evaluate the diagnostic and prognostic performance of a novel mRNA diagnostic/prognostic classifier (interprets the expression of 29 host response mRNA biomarkers) from whole blood in adult patients presenting to emergency departments (ED) with suspected infection.

NCT ID: NCT05399615 Withdrawn - Infectious Disease Clinical Trials

Detection of Bacterial and Viral Pathogens Infection Among Hospitalized Patients Feasibility Study

Infection
Start date: December 30, 2022
Phase: N/A
Study type: Interventional

Detection of bacterial and viral pathogens infection among hospitalized patients using breath analysis - feasibility study.

NCT ID: NCT05269134 Withdrawn - Clinical trials for Prosthetic Joint Infection

Bacteriophage Therapy in Patients With Prosthetic Joint Infections (PJI)

ACTIVE2
Start date: March 27, 2023
Phase: Phase 2
Study type: Interventional

This is a study designed to evaluate bacteriophage therapy in patients with chronic prosthetic joint infections.

NCT ID: NCT05269121 Withdrawn - Clinical trials for Bacterial Infections

Bacteriophage Therapy in First Time Chronic Prosthetic Joint Infections

ACTIVE1
Start date: September 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study will test the feasibility of a regimen of intraoperative (IO) and intravenous (IV) PhageBank™ bacteriophage therapy in conjunction with a DAIR procedure to cure chronic prosthetic joint infection (PJI) without replacement of the prosthesis.

NCT ID: NCT05085574 Withdrawn - COVID-19 Clinical Trials

Leidos-Enabled Adaptive Protocol for Clinical Trials (LEAP-CT) in Hospitalized Patients With COVID-19 (Addendum 1)

Start date: February 7, 2023
Phase: Phase 2
Study type: Interventional

This study is designed to test the efficacy and safety of combinations of two well-understood agents - famotidine and celecoxib in patients hospitalized with moderate-to-severe COVID-19 (based on World Health Organization [WHO] Ordinal Scale for Clinical Improvement). Both famotidine and celecoxib separately demonstrate clinical activity in mitigating COVID-19 disease symptoms or severity, and appear to have separate and complementary mechanisms of action.

NCT ID: NCT05026801 Withdrawn - Clinical trials for Respiratory Tract Infection Viral

Azithromycin Plus Hydroxychloroquine for COVID-19 Infection

Start date: February 8, 2021
Phase: Phase 3
Study type: Interventional

This is a randomized, double-blinded, Phase 3, multi-center trial of the clinical and microbiologic response of patients with a respiratory tract infection (RTI) due to coronavirus treated with a combination of azithromycin and hydroxychloroquine. Approximately 200 patients with symptoms of an RTI who test positive for SARS-CoV-2 by polymerase chain reaction (PCR) will receive a combination of azithromycin 500 mg and hydroxychloroquine 600 mg or matching placebos for six consecutive days. There will be two treatment regimens into which patients are randomized so that all patients will receive some active therapy.

NCT ID: NCT04983446 Withdrawn - Covid19 Clinical Trials

In-patient COVID-19 Study of Intranasal Foralumab

Start date: April 30, 2022
Phase: Phase 2
Study type: Interventional

This is a Phase 2, randomized, placebo-controlled, double-blind, proof-of-concept study of intranasal foralumab in hospitalized subjects with severe COVID-19 and pulmonary inflammation. Foralumab is a fully human second generation anti-CD3 mAb with a modified Fc unit (two amino acid substitutions) composed of 2 heavy chains with an immunoglobulin (Ig) G1constant region and 2 light chains with a kappa constant region. In a separate Phase 2 randomized, controlled, pilot trial conducted to assess safety, tolerability, and efficacy in 39 patients with mild to moderate COVID-19 in Brazil, showed that intranasal foralumab may be of benefit in modulating immune reactivity and in reducing pulmonary inflammation. Importantly, intranasal administration of foralumab was well tolerated with no clinically significant changes in blood cell counts (including blood lymphocytes), no evidence of hypersensitivity, and no serious adverse events (SAEs) were reported in the study.

NCT ID: NCT04979637 Withdrawn - Wound Heal Clinical Trials

Analytical Performance of pH, HNE and MPO Levels in Detecting Wound Infection Proof of Concept Biomarker Study

INDICATE
Start date: July 1, 2021
Phase:
Study type: Observational

The purpose of this study is to evaluate the effectiveness of a novel combination of biomarkers, pH/HNE/MPO, in detecting wound infection using the clinical judgement at 4 weeks as a standard of reference which will include a wound biopsy.